CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

Trial Identifier: D3612R00011
Sponsor: AstraZeneca
Start Date: October 2025
Primary Completion Date: December 2029
Study Completion Date: December 2029
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
South Korea, South Korea Busan, South Korea, South Korea, 49267
South Korea, South Korea Busan, South Korea, South Korea, 49241
South Korea, South Korea Busan, South Korea, South Korea, 34084
South Korea, South Korea Daejeon, South Korea, South Korea, 34943
South Korea, South Korea Daejeon, South Korea, South Korea, 35015
South Korea, South Korea Goyang-si, South Korea, South Korea, 10380
South Korea, South Korea Goyang-si, South Korea, South Korea, 10408
South Korea, South Korea Guri-si, South Korea, South Korea, 11923
South Korea, South Korea Incheon, South Korea, South Korea, 22332
South Korea, South Korea Incheon, South Korea, South Korea, 21565
South Korea, South Korea Seongnam-si, South Korea, South Korea, 13620
South Korea, South Korea Seoul, South Korea, South Korea, 06591
South Korea, South Korea Seoul, South Korea, South Korea, 03722
South Korea, South Korea Seoul, South Korea, South Korea, 02841
South Korea, South Korea Seoul, South Korea, South Korea, 06273
South Korea, South Korea Suwon-si, South Korea, South Korea, 16499
South Korea, South Korea Uijeongbu-si, South Korea, South Korea, 11765